Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tu Xu

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Public Health (Oxford, England)|June 26, 2026
Antibiotic exposure and cancer risk: an umbrella review elucidating the direction of risk across 14 malignanciesTu Xu, Qing Xin, Jiacheng Li, et al.
Computers in Biology and Medicine|November 29, 2023
Conduction and validation of a novel prognostic signature in cervical cancer based on the necroptosis characteristic genes via integrating of multiomics dataTu Xu, Jingwen Jiang, Xiaoqing Xiang, et al.
Journal of Alzheimer'S Disease : JAD|July 21, 2025
Application of machine learning reveals diagnostic biomarkers related to pyroptosis in Alzheimer's disease and analysis of immune infiltrationYujuan Huang, Tu Xu, Li Wang, et al.
Nature Communications|February 27, 2025
Big-data empowered traffic signal control could reduce urban carbon emissionKan Wu, Jianrong Ding, Jingli Lin, et al.
Therapeutic Innovation & Regulatory Science|August 8, 2025
Insights on Clinical Development of Cell and Gene Therapy for Rare Diseases-by DahShu Innovative Design Scientific Working Group (IDSWG)Chenkun Wang, Junrui Di, Mercedeh Ghadessi, et al.
Molecular Breeding : New Strategies in Plant Improvement|June 14, 2023
Genome-wide association analysis for grain moisture content and dehydration rate on maize hybridsYuan Dong, Zhi-Qian Feng, Fan Ye, et al.
Annals of the American Thoracic Society|August 22, 2024
Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2, Open-Label Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Annals of the American Thoracic Society|March 21, 2023
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2 Placebo-controlled Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Blood|October 27, 2018
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaCourtney D DiNardo, Keith Pratz, Vinod Pullarkat, et al.
The Lancet. Oncology|January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyCourtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Public Health (Oxford, England)|June 26, 2026
Antibiotic exposure and cancer risk: an umbrella review elucidating the direction of risk across 14 malignanciesTu Xu, Qing Xin, Jiacheng Li, et al.
Computers in Biology and Medicine|November 29, 2023
Conduction and validation of a novel prognostic signature in cervical cancer based on the necroptosis characteristic genes via integrating of multiomics dataTu Xu, Jingwen Jiang, Xiaoqing Xiang, et al.
Journal of Alzheimer'S Disease : JAD|July 21, 2025
Application of machine learning reveals diagnostic biomarkers related to pyroptosis in Alzheimer's disease and analysis of immune infiltrationYujuan Huang, Tu Xu, Li Wang, et al.
Nature Communications|February 27, 2025
Big-data empowered traffic signal control could reduce urban carbon emissionKan Wu, Jianrong Ding, Jingli Lin, et al.
Therapeutic Innovation & Regulatory Science|August 8, 2025
Insights on Clinical Development of Cell and Gene Therapy for Rare Diseases-by DahShu Innovative Design Scientific Working Group (IDSWG)Chenkun Wang, Junrui Di, Mercedeh Ghadessi, et al.
Molecular Breeding : New Strategies in Plant Improvement|June 14, 2023
Genome-wide association analysis for grain moisture content and dehydration rate on maize hybridsYuan Dong, Zhi-Qian Feng, Fan Ye, et al.
Annals of the American Thoracic Society|August 22, 2024
Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2, Open-Label Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Annals of the American Thoracic Society|March 21, 2023
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2 Placebo-controlled Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Blood|October 27, 2018
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaCourtney D DiNardo, Keith Pratz, Vinod Pullarkat, et al.
The Lancet. Oncology|January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyCourtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
Pageof 3